癌症研究
CD19
医学
淋巴瘤
弥漫性大B细胞淋巴瘤
细胞培养
药理学
临床试验
化学
细胞
药品
化学免疫疗法
联合疗法
作者
Zhimin Bai,Xiaoyu Huang,Xinfeng Wang,Yong Zhou,Zenghua Lin,H Liu
出处
期刊:Tumori Journal
[SAGE Publishing]
日期:2026-01-07
卷期号:: 3008916251408273-3008916251408273
标识
DOI:10.1177/03008916251408273
摘要
The XPO1 inhibitor KPT-330 exerts anti-cancer effects through stabilizing p53 and inhibiting the PI3K-AKT pathway, providing a molecular basis for DLBCL treatment. We may provide a potential promising combination therapy for the treatment of DLBCL with p53 mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI